22 octubre 2015
Using new, highly sensitive genomic sequencing technology, an international team of researchers has found new biological evidence to help explain why the malaria vaccine candidate RTS,S/AS01 (called RTS,S) provided only moderate protection among vaccinated children during clinical testing. The researchers found that genetic variability in the surface protein targeted by the RTS,S vaccine likely played a significant role.
http://www.sciencedaily.com/releases/2015/10/151022141713.htm
